SCHEMBL4837512

SCHEMBL4837512

Cc1c(Cl)cnc2[nH]c(-c3ccc(F)c([N+](=O)[O-])c3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 3/20 0.38
MAPT P10636 5/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
ADORA1 P30542 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ABCG2 Q9UNQ0 1/20 0.36
DHFR P00374 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HIF1A Q16665 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HCRTR1 O43613 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834855 0.87 GRK6 (0.41) NPBWR1MAPTADORA1NPC1RAB9A
SCHEMBL4834982 0.85 MAPT (0.39) NPBWR1MAPTLMNAHTTADORA1
SCHEMBL4841712 0.75 KDM4E (0.47) MAPTADORA1NPC1RAB9AALDH1A1
SCHEMBL28596575 0.74 MAPT (0.45) NPBWR1MAPTLMNAHTTADORA1
SCHEMBL4846517 0.71 GAA (0.39) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL4845766 0.69 MAPT (0.46) NPBWR1MAPTLMNAHTTNPC1
SCHEMBL4843765 0.68 TNKS (0.50) NPBWR1MAPTLMNAHTTNPC1
SCHEMBL23179595 0.67 DAO (0.47) MAPTHTTALDH1A1SMN1; SMN2
SCHEMBL20521410 0.66 PIN1 (0.45) MAPTLMNAHTTDHFRALDH1A1
SCHEMBL11579276 0.66 ALDH1A1 (0.67) MAPTLMNAHTTALDH1A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
EP-1539759-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016611-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 NPBWR1 3289/4885MAPT 3669/4885LMNA 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.